Top approved MS therapies in the U.S. by ARR 2014

Selected approved multiple sclerosis therapies as of 2014, ranked by ARR*

Show detailed source information?
Register for free
Already a member?
Log in

Use Ask Statista Research Service

Release date

July 2014


United States

Survey time period


Supplementary notes

* ARR = annualized relapse rate.
** For mitoxantrone, the primary outcome measure for efficacy in the progressive types of MS was a composite of five elements: Expanded Disability Status Scale (EDSS) scores, Ambulation Index, number of relapses requiring treatment with steroids, months to first relapse needing treatment with steroids, and Standard Neurological Status. Data in the table for mitoxantrone have been extracted from the study; however, these were not the primary outcome measures.
***ARR for Tecfidera ranges from 44 to 53.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

Other statistics that may interest you Statistics on

About the industry


About the region


Selected statistics


Other regions


Related statistics


Further related statistics

Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.